Start Over

The prevalence, operations, and outcomes of carcinoid heart disease.

Authors :: Macfie R
McCully BH
Ratzlaff AN
Lim J
Song HK
Dewey EN
Pommier SJ
Bhamidipati CM
Pommier RF
Source :: American journal of surgery [Am J Surg] 2022 Aug; Vol. 224 (2), pp. 665-669. Date of Electronic Publication: 2022 Mar 31.
Publication Year :: 2022
Abstract: Background: Carcinoid heart disease (CHD) is a sequela of carcinoid liver metastases (LM). The true prevalence of CHD is unknown due to infrequent screening by transthoracic echocardiography (TTE). Octreotide is believed to protect against new and recurrent CHD, but supporting data are scant. This study determined CHD prevalence and outcomes in patients screened by TTE and treated with octreotide.<br />Methods: Records of carcinoid patients from 2001 to 2021 were reviewed. Survival was estimated by Kaplan-Meyer curves and compared by log-rank.<br />Results: Among 282 patients screened by TTE, overall survival was lower in CHD (n = 40) versus non-CHD (n = 242) patients (p < 0.001). Despite octreotide therapy, 21 patients developed CHD. Among patients with inoperable LM, survival was lower in CHD patients without valve replacement (VR) (p < 0.001), but similar between CHD patients with VR and non-CHD patients. CHD patients with VR and hepatic cytoreduction had survival similar to CHD patients without VR.<br />Conclusion: VR improves survival in CHD patients with inoperable LM. Hepatic cytoreduction after VR should be reserved for carefully selected cases. Our data do not support a protective effect of octreotide.<br /> (Copyright © 2022 Elsevier Inc. All rights reserved.)